Art

J-GLOBAL ID：201802216293653652   Reference number：18A0827497

Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan

日本における進行性乳癌に及ぼすベバシズマブの効果の予測因子としての高血圧と蛋白尿

Author (9)： Tanaka Hiroaki (Department of Pharmacy, Kagawa University Hospital) ,  Takahashi Koichi (Department of Pharmacy, Kagawa University Hospital) ,  Yamaguchi Kazunori (Department of Pharmacy, Kagawa University Hospital) ,  Kontani Keiichi (Department of Respiratory, Breast and Endocrine Surgery, Kagawa University Hospital) ,  Motoki Takahiro (Department of Pharmacy, Kagawa University Hospital) ,  Asakura Masato (Department of Pharmacy, Kagawa University Hospital) ,  Kosaka Shinji (Department of Pharmacy, Kagawa University Hospital) ,  Yokomise Hiroyasu (Department of Respiratory, Breast and Endocrine Surgery, Kagawa University Hospital) ,  Houchi Hitoshi (Department of Pharmacy, Kagawa University Hospital)
Material： Biological and Pharmaceutical Bulletin (Web)
Volume： 41  Issue： 4  Page： 644-648(J-STAGE)  Publication year： 2018 
JST Material Number： U1402A  ISSN： 1347-5215  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *Bevacizumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0827497&from=J-GLOBAL&jstjournalNo=U1402A") }}

Author keywords (8)： bevacizumab ,  advanced breast cancer ,  hypertension ,  proteinuria ,  bevacizumab ,  advanced breast cancer ,  hypertension ,  proteinuria

JST classification (1)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (20)：

• 1) AVASTIN package insert, Chugai Pharmacy, Tokyo, Japan (May 2016).
• 2) Sane DC, Anton L, Brosnihan KB. Angiogenetic growth factors and hypertension. Angiogenesis, 7, 193-201 (2004).
• 3) Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin. Drug Saf., 5, 553-566 (2006).
• 4) Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaqqin SE. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med., 358, 1129-1136 (2008).
• 5) Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med., 357, 2666-2676 (2007).

Terms in the title (6)： 日本 ,  進行性乳癌 ,  ベバシズマブ ,  予測因子 ,  高血圧 ,  蛋白尿